Trial reportThe European respiratory journal2017
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
Trial report in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Efficacy and safety of mucolytic agents in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Romanian clinical guideline for diagnosis and treatment of COPD.The Journal of international medical research · 2020Guideline
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Dongtian Changchun ointment for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.Nature communications · 2024Trial
- Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.International journal of chronic obstructive pulmonary disease · 2019Trial
- Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial.International journal of chronic obstructive pulmonary diseaseTrial
- Effects of hypertonic saline and/or carbocisteine on sputum rheology in bronchiectasis: CLEAR-EME.ERJ open research · 2026Article
- Preventing mucus plugs in COPD: a potential role for erdosteine.The European respiratory journal · 2026Article
- Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mucus Plugging as a Treatable Trait Across the Asthma-COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging.Biomedicines · 2026Review
- Interaction of Erdosteine with TrkA Signaling Pathways: Implications for Analgesia.International journal of molecular sciences · 2025Article
- Antiviral Effect of Erdosteine in Cells Infected with Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2025Article
- Pharmacologic Therapies for Preventing Chronic Obstructive Pulmonary Disease Exacerbations: A Comprehensive Review.Tuberculosis and respiratory diseases · 2025Article
- New instrument for effective detection of a history of COPD exacerbations, including usually unreported events.Frontiers in medicine · 2025Article
- Impact of Airway-Occluding Mucus Plugs on Mortality in Patients with COPD According to Disease Severity: A Subset Analysis of Data From COPDGene.International journal of chronic obstructive pulmonary disease · 2025Article
- Management of acute exacerbations of COPD in the emergency department and its associations with clinical variables.Internal and emergency medicine · 2024Article
- Potential of gut microbiota metabolites in treating COPD: network pharmacology and Mendelian randomization approaches.Frontiers in microbiology · 2024Article
- Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.Respiratory research · 2023Review
- Bilirubin-associated single nucleotide polymorphism (SNP) and respiratory health outcomes: a mendelian randomization study.Respiratory research · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory volume in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.